It enables excellent systemic movement of the active ingredient through the plant to the site of action against fungal cells.
ADAMA has announced the launch of a novel prothioconazole fungicide which uses a unique formulation to offer improved cereal and OSR disease control compared to the current market leader. Soratel (250 g/l prothioconazole), features ADAMA’s new ‘AsorbitalTM’ formulation technology: comprising a unique combination of two solvents and an adjuvant, this novel formulation, which was developed at ADAMA’s global R&D facility at Neot Hovav, Israel, improves uptake of the fungicide into the leaf and enables excellent systemic movement of the active ingredient through the plant to the site of action against fungal cells.
“With the spring rapidly approaching, our global research and development and product registration teams have been working around the clock to make Soratel available to UK growers in time for the new spraying season,” explains Mel Wardle, ADAMA’s fungicide product manager in the UK.
“Our mission wasn’t simply to bring yet another generic prothioconazole product to the market, but to develop an all-new formulation of this tried and tested active ingredient that offers real and tangible benefits above and beyond those already available from other prothioconazole based fungicides.”
EU trials have shown that, gramme for gramme per hectare, Soratel consistently and reliably provides a notable improvement in disease control under a range of conditions compared to the current market leading prothioconazole product, Wardle adds.
“Specifically, under UK conditions, trials have shown that Soratel is up to 13% more efficacious against fusarium than the current market leader, with similar results also reported when used to treat sclerotinia in oilseed rape growing in a maritime climate,” she explained.
Wardle added, “It offers a flexible range of application opportunities in cereals and oilseed rape and can be used at a wide range of treatment timings to provide improved protection against a broad spectrum of key diseases.”
